BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Editas and Vertex Ink Deal for Cas9 License for $50M Upfront

  December 13, 2023

   · 

  1 min read
• 

  Headed to JPM? Here Are Some Tips to Make the Most of It

  BioSpace spoke with industry professionals about how to make your time in San Francisco valuable.

  December 13, 2023

   · 

  3 min read

   · 

  Tyler Patchen
• 

  Policy

  FDA Action Alert: Calliditas, Ionis/AstraZeneca, Amgen and More

  The year may be coming to a close, but there’s no holiday break for the FDA, which will release five regulatory verdicts over the next two weeks.

  December 13, 2023

   · 

  4 min read

   · 

  Tristan Manalac
• 

  Business

  Pfizer’s 2024 Outlook Disappoints Wall Street, Plans $500M in Additional Cost Cuts

  The biopharma giant provided full-year 2024 guidance on Wednesday that fell below Wall Street’s expectations, as it continues a cost-cutting effort now up to $4 billion in total.

  December 13, 2023

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Policy

  Oncologists Defend CAR-T After FDA Advisory

  The agency is investigating reports of secondary blood cancers in patients who have received certain CAR T cell therapies, but experts say the risk is low and is outweighed by the terminal nature of some cancers.

  December 13, 2023

   · 

  6 min read

   · 

  Jill Neimark
• 

  Career Advice

  How to Assess a Company’s DEI Commitment as a Candidate

  Here’s what to look for—and what to ask—before and during the interview process to find out whether an employer fosters an inclusive environment.

  December 13, 2023

   · 

  3 min read

   · 

  Nadia Bey
• 

  Editas and Vertex Ink Deal for Cas9 License for $50M Upfront

  The deal follows the FDA approval of Vertex’s gene-editing sickle cell treatment and Editas’ earlier legal battle over rights to the technology.

  December 13, 2023

   · 

  1 min read

   · 

  Tyler Patchen
• 

  How to Cope with Layoffs and Other Career Setbacks

  Being laid off, experiencing a trial failure or failing to secure funding can feel crushing. Here’s how to maintain perspective and move on.

  December 13, 2023

   · 

  4 min read

   · 

  Mollie Barnes
• 

  As Its Domestic Market Grows, South Africa Moves Toward Greater Local Biopharmaceutical Production

  Partnerships with companies based in the U.S. and elsewhere are one factor driving growth in the industry, but obstacles remain.

  December 13, 2023

   · 

  5 min read

   · 

  Patience Asanga
• 

  FDA

  Major FDA approvals for Vertex/CRISPR; bluebird gets black box warning and price scrutiny

  This week, we discuss the two major FDA approvals for sickle cell from Vertex/CRISPR and bluebird bio; Axcella and the future of long-covid treatments, Vanda’s $100m purchase and AI regulatory developments in Europe.

  December 13, 2023

   · 

  1 min read

   · 

  Lori Ellis